商品情報にスキップ
1 2

Pfizer and the Spinoff of Upjohn

通常価格 ¥1,144 JPY
通常価格 セール価格 ¥1,144 JPY
セール 売り切れ
税込み。
書籍サイズ
ページ数

In July 2019, Pfizer announced that it would spin off its Upjohn division and merge it with Mylan, a specialty and generic drugs firm. Within Pfizer, the Upjohn business unit was a conduit for Pfizer drugs going off-patent. Divesting the Upjohn business would allow Pfizer to focus on innovative drugs and exit the generics sector. Combining Upjohn with Mylan would create a new company that would compete in branded prescription drugs, generics, biosimilars, and over-the-counter medicines. Cost synergies from the merger of $1 billion were projected. Under the terms of the agreement, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%.

【書誌情報】

ページ数:12ページ

サイズ:A4

商品番号:HBSP-TB0585

発行日:2020/1/1

登録日:2020/3/24

1 3